South San Francisco, California, April 9, 2026 /PRNewswire/ — Human Longevity, Inc. (HLI), a global leader in precision health and longevity medicine, today announced that artificial intelligence pioneer and Nobel Prize-winning scientist Jeffrey Hinton has joined the company as a scientific advisor. In this role, Dr. Hinton will help guide HLI’s AI strategy to build a next-generation platform for disease risk prediction and early detection.
Widely regarded as one of the “godfathers of AI,” Dr. Hinton won the 2024 Nobel Prize in Physics for his fundamental contributions to machine learning and neural networks, the technologies that underpin today’s artificial intelligence revolution.
His appointment underscores Human Longevity’s strategic focus on building category-defining AI world models that leverage one of the world’s most comprehensive longitudinal datasets, integrating genomics, advanced imaging, and multi-omic biomarkers.
“We are honored to have Dr. Hinton as an advisor on human longevity,” said Dr. He Weiwu, HLI’s Executive Chairman. “Artificial intelligence is at the core of everything we do. I strongly believe that AI will transform healthcare. Dr. Hinton’s pioneering work has laid the foundation for this revolution. His insights will be invaluable as we develop the next generation of predictive models that detect disease earlier and help people live longer, healthier lives.”
Human Longevity has spent more than a decade building one of the world’s most comprehensive longitudinal datasets, spanning whole genome sequencing, advanced imaging, clinical biomarkers, and deep phenotypic insights. By applying cutting-edge artificial intelligence to this unparalleled dataset, HLI is redefining healthcare, moving from reactive “disease treatment” to predictive, personalized disease prevention.
This vision reached a major milestone with the release of HLI’s AI-powered longevity app in early 2026. my healthextending these capabilities beyond the clinic and into everyday life.
“At Human Longevity, we are not only predicting disease early, but also deciphering why some people are able to stay healthy,” he added. “With Dr. Hinton’s leadership, we aim to accelerate the development of AI systems that uncover hidden biological patterns and fundamentally change the way we understand human health and aging.”
“I’m excited to be joining Human Longevity at a time when artificial intelligence and biology are converging in unprecedented ways,” said Jeffrey Hinton. “I believe that AI will fundamentally transform healthcare. Founded by visionary genomics pioneer Dr. J. Craig Venter, Human Longevity is a company that uses large-scale genomic data, imaging data, and biomarkers. By integrating data and advanced machine learning approaches, we are uniquely positioned to lead this transformation, which has the potential to redefine disease risk prediction and enable truly personalized healthcare.”
About Human Longevity Co., Ltd.
Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, artificial intelligence, and multimodal diagnostics to extend the healthy human lifespan. Through our flagship executive health program and growing portfolio of longevity programs, HLI provides comprehensive, data-driven assessments aimed at identifying and reducing disease risk long before symptoms appear. The company is working to redefine healthcare through AI-powered proactive diagnostics and personalized preventive care.
For more information, please visit www.humanlongevity.com.
Media contact:
[email protected]
www.humanlongevity.com
Source Human Longevity Co., Ltd.
